Entrada Therapeutics Inc. has released a corporate presentation detailing its significant clinical momentum throughout 2025. The company anticipates having four active clinical programs by the end of the year, with notable advancements in its Duchenne muscular dystrophy (DMD) franchise. Clinical studies for ENTR-601-44 have been authorized in the UK, EU, and US, while ENTR-601-45 has been authorized in the UK and EU. Additionally, ENTR-601-50 is on track for global regulatory filings in the second half of 2025. Entrada is also advancing its preclinical pipeline, which includes programs targeting ocular diseases. The company maintains a strong financial position, with a cash balance of approximately $383 million, expected to support operations into the second quarter of 2027. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。